SciSparc Ltd., a clinical-stage pharmaceutical company, announced on August 14, 2024, that it has entered into an addendum to its previously announced Merger Agreement with AutoMax Motors Ltd. and SciSparc Merger Sub Ltd. The addendum extends the deadline to terminate the Merger Agreement from August 30, 2024, to November 30, 2024, if the merger is not consummated by then. Additionally, the Jerusalem District Court has approved AutoMax's petition to hold special class meetings of its shareholders to vote on the merger. SciSparc, which specializes in developing therapies for central nervous system disorders and rare diseases, also owns a controlling interest in a subsidiary selling hemp seed oil-based products on Amazon.com. The company's forward-looking statements indicate progress but also acknowledge risks and uncertainties that could affect the completion of the merger.

SciSparc Ltd., a clinical-stage pharmaceutical company, announced on August 14, 2024, that it has entered into an addendum to its previously announced Merger Agreement with AutoMax Motors Ltd. and SciSparc Merger Sub Ltd. The addendum extends the deadline to terminate the Merger Agreement from August 30, 2024, to November 30, 2024, if the merger is not consummated by then. Additionally, the Jerusalem District Court has approved AutoMax's petition to hold special class meetings of its shareholders to vote on the merger. SciSparc, which specializes in developing therapies for central nervous system disorders and rare diseases, also owns a controlling interest in a subsidiary selling hemp seed oil-based products on Amazon.com. The company's forward-looking statements indicate progress but also acknowledge risks and uncertainties that could affect the completion of the merger.